# Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Source: https://onco.cc/trials/nct00769704/  
OnCo record `nct00769704` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Talimogene laherparepvec and Sargramostim in Melanoma, run by BioVex Limited, completed.

## Summary

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma is a phase 3 interventional study registered as NCT00769704 by BioVex Limited, with 437 participants recorded, started 2009-04 and reaching its primary completion in 2013-02. Interventions recorded: Talimogene laherparepvec, GM-CSF. Conditions recorded: Melanoma.

Linked to the drug Talimogene laherparepvec because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00769704
- Phase: 3
- Setting: A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
- Sponsor: BioVex Limited
- Enrolled: 437

## Sources

- ClinicalTrials.gov NCT00769704: https://clinicaltrials.gov/study/NCT00769704

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Sargramostim](https://onco.cc/drugs/sargramostim/), [Talimogene laherparepvec](https://onco.cc/drugs/talimogene-laherparepvec/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct00769704.json